Pfizer Aurobindo Deal

PFIZER has entered into a series of agreements with Aurobindo Pharma to market medicines that are no longer patent protected and don’t have market exclusivity in the US and Europe. Pfizer will take on licence, an array of generic pills and injectible medicines, as it looks to off-patent medicines for the growth, said a senior executive on Tuesday, adding that it is focusing on such off-patent medicines to increase profits.
The company estimates that the deal with Aurobindo would boost its revenue by $200 million till 2014. "Aurobindo will manufacture the products and we will be responsible for the marketing," said Pfizer senior vice-president Kevin Cooper. "Currently, this is for the US and Europe market but we are also in talks for other geographies as well." Pfizer’s established products business unit was launched in 2008, as part of the company’s initiative to create smaller, more accountable business units aligned with customer needs. It is part of its generics subsidiary Greenstone, which currently has 300 products in its basket, including former blockbusters such as Zoloft for depression, Norvasc for high blood pressure, Zithromax for bacterial infections and Medrol for inflammatory and immune conditions such as asthma, arthritis and lupus. Pfizer’s deal with Aurobindo is its first in-licensing deal where the US-based pharma giant takes on licence, products from Aurobindo. "We consciously chose to in-licence generic products that we did not develop in-house. We looked at Aurobindo’s manufacturing facilities and are happy with them," said Mr Cooper. ink marketing deal